• Home
  • Medinfo
  • Emergency extemporaneous preparation of oral suspension from Tamiflu capsules

Emergency Extemporaneous Preparation of Oral Suspension from Tamiflu Capsules

This article responds to your request for information on the emergency extemporaneous preparation of oral suspension from Tamiflu® (oseltamivir) capsules.

Download article Download

Last updated August 11, 2023

Tamiflu formulation recommendation

Tamiflu powder for oral suspension (6 mg/mL) is indicated for use in

  • pediatric patients
    • adult patients who have difficulty swallowing capsules, or
      • patients in need of lower doses.

        Compounding oral suspension

        Oral suspension may be compounded from Tamiflu capsules in emergency situations if directed by the healthcare provider. The instructions below provide guidance on how to prepare a 6 mg/mL oral suspension for a 5-day course based on

        • the patient weight
          • various Tamflu capsule strengths, and
            • the amount of water containing 0.05% w/v sodium benzoate.[1]

              Purpose of sodium benzoate

              Sodium benzoate acts as a preservative for the oral suspension.

              Instructions for preparing the oral suspension:

              1. Transfer the contents of the appropriate number of Tamiflu capsules into the bottle (Table 1).

              2. Add the appropriate volume of water with sodium benzoate solution (Table 1).

              3. Close the bottle with the cap and shake for 2 minutes.

              4. Pull an ancillary label on the bottle indicating "Shake gently before use".

              5. Place an appropriate expiration date label according to the storage conditions.

              6. Instruct the parent or caregiver to discard any remaining solutino after the patient has completed the full course of therapy.


               Table 1. Number of capsules and amount of vehicle needed to prepare the total volume of 6 mg/mL suspension

              Body weight, Total volume, Required number of Tamiflu capsules (mg of oseltamivir)
               *We have no data on mixing capsule at this strength to obtain the target concentration since whole numbers of capsules cannot be used to achieve the target concentration. Please use an alternate capsule strength.

              Storage of compounded oral suspension

              Room temperature storage conditions

              The compounded oral suspension is stable for 3 weeks, or 21 days, when stored at room temperature.[1] Do not store above 25ºC.

              Refrigerated storage conditions

              The compounded oral suspension is stable for 6 weeks when stored at 2ºC to 8ºC.[1]

              Other external stability studies

              Other external studies have evaluated the preparation and stability of Tamiflu in various extemporaneous liquid preparations.[2,3]


              1. Roche Internal Regulatory Document. (Accessed on 11Jul2023).

              2. Ford SPBB, Kloesel LRBF, Grabenstein JRP. Stability of oseltamivir in various extemporaneous liquid preparations. Int J Pharm Compd 11:162-74. https://www.ncbi.nlm.nih.gov/pubmed/23974623

              3. Winiarski A, Infeld M, Tscherne R, et al. Preparation and stability of extemporaneous oral liquid formulations of oseltamivir using commercially available capsules. J Am Pharm Assoc (2007) 47:747-55. https://www.ncbi.nlm.nih.gov/pubmed/18032138

              Welcome to Medically

              The Roche Science Hub

              This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management. It is intended for healthcare professionals.

              Not a healthcare professional? Browse:

              This global website is intended for healthcare professionals outside the UK, US, Canada and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same.

              You are Leaving Medically

              By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.